Sanofi Has Collaborated With Radiomedix And Orano Med For Alphamedix (212Pb-DOTAMTATE), For Neuroendocrine Tumors, Radiomedix And Orano Med Will Receive An Upfront Payment Of €100M And Up To €220M In Sales Milestones
Sanofi Has Collaborated With Radiomedix And Orano Med For Alphamedix (212Pb-DOTAMTATE), For Neuroendocrine Tumors, Radiomedix And Orano Med Will Receive An Upfront Payment Of €100M And Up To €220M In Sales Milestones
賽諾菲與Radiomedix和Orano Med合作開發Alphamedix (212Pb-DOTAMTATE)用於神經內分泌腫瘤，Radiomedix和Orano Med將獲得1億歐元的預付款和高達2.2億歐元的銷售里程碑獎勵。
Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development
根據許可協議，賽諾菲將負責AlphaMedix的全球商業化，而Orano Med將負責通過其目前正在開發的全球工業平台製造AlphaMedix
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。